Integrate artificial intelligence (AI) and multi-omics excellence to create novel Drug/Diagnostic combinations that improve treatment of cancer patients.
Our AI-assisted and multi-omics-based platform enables the identification of modulators and mediated biological functions of the master immune regulator Arylhydrocarbon Receptor (AHR) pan-cancer and in response to cancer immunotherapies.
cAHRmeleon Bioscience GmbH is an innovative new biotech company founded in December 2021, as a spin-off of the German Cancer Research Center (DKFZ) in Heidelberg, Germany.
Overcomes cell and ligand type specificity
Validated in 32 cancers
Transferable across multi-omics layers
We extensively profiled multiple activators of the AHR and the subsequent transcriptional responses across multiple tissues and cancers.
We possess a broad database of AHR signatures. This database enables us to investigate AHR activity in cancer and autoimmune diseases.
Our bioinformatics platform analyses high throughput data for AHR activation and functions from gene expression, proteome and metabolome data.
Our AI-AHR technology supports patient stratifictaion to therapy and the pediction of patients‘ therapy response.
Contact us for more information